Archived explainer. For the current picture see today's VKTX page.
VIKING THERAPEUTICS (VKTX) is drawing unusual attention today. Our newswire has captured 1 story on VKTX across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100).
VKTX stock is moving lower today amid mixed signals from the market and recent insider activity. The stock has declined 66% from its 52-week high of $43.15 and is trading near the lower end of its range at $22.96. Recent analyst activity has included both a lowered price target from JPMorgan and a raised target from Canaccord Genuity, while insider sales by top executives have added to investor uncertainty.
Viking Therapeutics is facing a period of volatility as the stock continues to trade below its peak. The company reported Q2 earnings of $(1.10) per share, which beat the estimate of $(1.25), but remains unprofitable with a trailing twelve-month EPS of -4.67. JPMorgan has maintained an Overweight rating on the stock but reduced its price target to $65, while Canaccord Genuity has kept a Buy rating and raised its target to $114. These diverging views reflect ongoing uncertainty about the company’s clinical trial outcomes and the potential for its lead drug candidate to deliver on early promise.
Insider transactions have also drawn attention. On July 29, 2026, Viking’s COO, CEO, and CFO each sold shares, marking the third instance of insider sales in the last 90 days. These sales totaled $6.3 million and occurred without any corresponding buy activity, signaling a lack of confidence from company leadership.
The stock has traded in a 52-week range of $22.96 to $43.15 and has a market capitalization of $3.8 billion. With a beta of 0.68, it is less volatile than the broader market. The 30-day average sentiment score is 50 out of 100, while the seven-day score has dropped to 41, indicating a recent deterioration in market sentiment. This aligns with the downward pressure on the stock.
Investors should monitor Viking Therapeutics’ clinical trial data and any further analyst commentary. The stock remains speculative, and its performance will likely depend on the strength of its pipeline and the market’s reaction to upcoming developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
More on VKTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier VKTX move explainers: 2026-08-31